Suppr超能文献

基于生物信息学、荟萃分析和实验验证的肝细胞癌中miR-101-3p靶点鉴定及功能特征研究

Identification of miR-101-3p targets and functional features based on bioinformatics, meta-analysis and experimental verification in hepatocellular carcinoma.

作者信息

Li Chun-Yao, Pang Yu-Yan, Yang Hong, Li Jia, Lu Hai-Xia, Wang Han-Lin, Mo Wei-Jia, Huang Lan-Shan, Feng Zhen-Bo, Chen Gang

机构信息

Department of Pathology, The First Affiliated Hospital of Guangxi Medical University6 Shuangyong Road, Nanning 530021, Guangxi Zhuang Autonomous Region, China.

Department of Medical Ultrasonics, The First Affiliated Hospital of Guangxi Medical University6 Shuangyong Road, Nanning 530021, Guangxi Zhuang Autonomous Region, China.

出版信息

Am J Transl Res. 2017 May 15;9(5):2088-2105. eCollection 2017.

Abstract

BACKGROUND

MiR-101-3p has been reported to suppress invasion and metastasis in hepatocellular carcinoma (HCC) cells. However, the relevant mechanisms are still unclear. The research seeks to determine systematic value of miR-101-3p in HCC, and comprehensively summarize the predicted target genes as well as their potential function, pathways and networks in HCC.

METHODS

The miR-101-1 profiles in 353 HCC patients from The Cancer Genome Atlas (TCGA) were analyzed. Meta-analysis was performed to estimate relationship of miR-101 (including precursor and mature miR-101) with clinical features and prognosis in HCC. Further, the promising targets of miR-101-3p were predicted and followed with Gene Ontology (GO), pathway and network analysis. In addition, the functional impact of miR-101-3p was confirmed with experiments in HCC cells.

RESULTS

In TCGA data, low-expression of miR-101-1 might be a diagnostic (AUC: 0.924, 95% CI: 0.894-0.953) and prognostic (HR=1.55) marker for HCC. Down-regulated miR-101-1 also correlated with poor differentiation, advanced TNM stage, lymph node metastasis and high AFP level of HCC. Meta-analysis revealed that miR-101 down-regulation were associated with poor prognosis, high AFP level and advanced TNM stage of HCC. Moreover, 343 hub genes were filtered and miR-101-3p may be involved in intracellular signaling cascade, transcription, metabolism and cell proliferation. Focal adhesion and pathways in cancer were also significantly enriched. experiments demonstrated that miR-101-3p inhibited proliferation and promoted apoptosis in HCC cells.

CONCLUSIONS

MiR-101-1 may be a prospective biomarker for diagnosis and prognosis of HCC. Potential targets of miR-101-3p could regulate genesis and development of HCC. The data offers insights into biological significances and promising targets of miR-101-3p for further investigation and potential therapies in HCC.

摘要

背景

据报道,miR-101-3p可抑制肝癌(HCC)细胞的侵袭和转移。然而,相关机制仍不清楚。本研究旨在确定miR-101-3p在肝癌中的系统价值,并全面总结其预测的靶基因及其在肝癌中的潜在功能、途径和网络。

方法

分析了来自癌症基因组图谱(TCGA)的353例肝癌患者的miR-101-1图谱。进行荟萃分析以评估miR-101(包括前体和成熟miR-101)与肝癌临床特征和预后的关系。此外,预测了miR-101-3p的潜在靶标,并进行了基因本体论(GO)、途径和网络分析。另外,通过肝癌细胞实验证实了miR-101-3p的功能影响。

结果

在TCGA数据中,miR-101-1低表达可能是肝癌的诊断(AUC:0.924,95%CI:0.894-0.953)和预后(HR=1.55)标志物。miR-101-1下调还与肝癌的低分化、晚期TNM分期、淋巴结转移和高AFP水平相关。荟萃分析显示,miR-101下调与肝癌的不良预后、高AFP水平和晚期TNM分期相关。此外,筛选出343个枢纽基因,miR-101-3p可能参与细胞内信号级联、转录、代谢和细胞增殖。粘着斑和癌症途径也显著富集。实验表明,miR-101-3p抑制肝癌细胞增殖并促进其凋亡。

结论

miR-101-1可能是肝癌诊断和预后的潜在生物标志物。miR-101-3p的潜在靶标可调节肝癌的发生和发展。这些数据为miR-101-3p在肝癌进一步研究和潜在治疗中的生物学意义及有前景的靶标提供了见解。

相似文献

5
A comprehensive insight into the clinicopathologic significance of miR-144-3p in hepatocellular carcinoma.
Onco Targets Ther. 2017 Jul 11;10:3405-3419. doi: 10.2147/OTT.S138143. eCollection 2017.
9
MiR-542-3p inhibits metastasis and epithelial-mesenchymal transition of hepatocellular carcinoma by targeting UBE3C.
Biomed Pharmacother. 2017 Sep;93:420-428. doi: 10.1016/j.biopha.2017.06.070. Epub 2017 Jun 27.

引用本文的文献

1
Inferring single-cell and spatial microRNA activity from transcriptomics data.
Commun Biol. 2025 Jan 18;8(1):87. doi: 10.1038/s42003-025-07454-9.
2
Genetic and Epigenetic Mechanisms Deregulate the CRL2 Complex in Hepatocellular Carcinoma.
Front Genet. 2022 May 18;13:910221. doi: 10.3389/fgene.2022.910221. eCollection 2022.
4
Comprehensive analysis of GSEC/miR-101-3p/SNX16/PAPOLG axis in hepatocellular carcinoma.
PLoS One. 2022 Apr 28;17(4):e0267117. doi: 10.1371/journal.pone.0267117. eCollection 2022.
6
Bone Mesenchymal Stem Cells Promote Extracellular Matrix Remodeling of Degenerated Nucleus Pulposus Cells the miR-101-3p/EIF4G2 Axis.
Front Bioeng Biotechnol. 2021 Aug 27;9:642502. doi: 10.3389/fbioe.2021.642502. eCollection 2021.
8
Glycogen Phosphorylase B Is Regulated by miR101-3p and Promotes Hepatocellular Carcinoma Tumorigenesis.
Front Cell Dev Biol. 2020 Nov 25;8:566494. doi: 10.3389/fcell.2020.566494. eCollection 2020.

本文引用的文献

2
MicroRNA-101 sensitizes hepatocellular carcinoma cells to doxorubicin-induced apoptosis via targeting Mcl-1.
Mol Med Rep. 2016 Feb;13(2):1923-9. doi: 10.3892/mmr.2015.4727. Epub 2015 Dec 28.
3
Silencing of WWP2 inhibits adhesion, invasion, and migration in liver cancer cells.
Tumour Biol. 2016 May;37(5):6787-99. doi: 10.1007/s13277-015-4547-z. Epub 2015 Dec 10.
5
MiRNA-101 inhibits breast cancer growth and metastasis by targeting CX chemokine receptor 7.
Oncotarget. 2015 Oct 13;6(31):30818-30. doi: 10.18632/oncotarget.5067.
7
Argonaute 2 promotes angiogenesis via the PTEN/VEGF signaling pathway in human hepatocellular carcinoma.
Acta Pharmacol Sin. 2015 Oct;36(10):1237-45. doi: 10.1038/aps.2015.18. Epub 2015 May 4.
9
Systemic delivery of microRNA-101 potently inhibits hepatocellular carcinoma in vivo by repressing multiple targets.
PLoS Genet. 2015 Feb 18;11(2):e1004873. doi: 10.1371/journal.pgen.1004873. eCollection 2015 Feb.
10
Global cancer statistics, 2012.
CA Cancer J Clin. 2015 Mar;65(2):87-108. doi: 10.3322/caac.21262. Epub 2015 Feb 4.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验